Australian company Certa Therapeutics has announced that the US FDA has granted Fast Track Designation for its investigational therapy FT011 for treating systemic sclerosis.
Certa Therapeutics’ FT011 granted US FDA fast track for systemic sclerosis
February 19, 2024 Latest NewsAustralian Biotech
Latest Video
New Stories
-
CSL expands US manufacturing with $1.5bn investment to boost plasma therapy production
March 10, 2026 - - Latest News -
Labor’s FoI backdown is a welcome victory for transparency and accountability
March 10, 2026 - - Latest News -
Mark Butler steps in to block eye injection funding change after patient warnings
March 10, 2026 - - Latest News -
Pharmac says new agreement has improved access to treatment for New Zealanders
March 10, 2026 - - Latest News -
Island Pharmaceuticals expands antiviral program through Burnet Institute collaboration
March 9, 2026 - -
New cancer research highlights potential of narmafotinib to koost KRAS Inhibitor therapies
March 9, 2026 - - Australian Biotech -
Lateral Pharma secures key U.S. patent for novel neuropathic pain therapy
March 9, 2026 - - Australian Biotech

